The latest update is out from GlaxoSmithKline ( (GB:GSK) ).
GSK announced that the European Medicines Agency has accepted its application to expand the use of Nucala (mepolizumab) for treating COPD with an eosinophilic phenotype. The application is backed by the successful phase III MATINEE trial, which demonstrated a significant reduction in moderate/severe exacerbations in COPD patients. If approved, Nucala could become the first monthly biologic treatment for COPD, addressing a major need for targeted therapies in a disease affecting over 40 million people in Europe.
More about GlaxoSmithKline
GSK is a global biopharma company focused on uniting science, technology, and talent to advance healthcare. It has an industry-leading respiratory portfolio and is dedicated to improving outcomes for people with respiratory diseases, including asthma and COPD.
YTD Price Performance: 13.33%
Average Trading Volume: 8,806,428
Technical Sentiment Signal: Strong Sell
Current Market Cap: £61.4B
See more insights into GSK stock on TipRanks’ Stock Analysis page.